https://www.selleckchem.com/pr....oducts/calpeptin.htm
05; P .001), pre-ICH mRS score (OR, 1.62; 95% CI, 1.41-1.87; P .001), lobar location (OR, 0.22; 95% CI, 0.16-0.30; P .001), and presence of infection (OR, 1.85; 95% CI, 1.42-2.41; P .001). The findings of this cohort study validate ICH score elements and suggest additional baseline and interim patient characteristics were associated with variation in 3-month outcome. The findings of this cohort study validate ICH score elements and suggest additional baseline and interim patient characteristics were associated with
Like
Comment
Share
